I still remember the feeling last September when we added CVS Health to the Bullpen. The valuation looked reasonable, the dividend felt solid, and the new leadership seemed to be steadying the ship after years of noise. Fast forward to this week and that thesis has taken a serious hit. Wednesday’s session delivered one of those rare market-wide resets that force you to re-examine almost every position. Stocks jumped hard after the midterm results became clearer, the S&P 500 climbing roughly 1.7 percent, yet not every name participated in the same way. Some stories improved. Others, like CVS, suddenly looked a lot more complicated.
What Really Moved Markets After The Midterms
The election outcome acted like a giant clearing event. Investors had spent weeks pricing in uncertainty, and once the results pointed toward Democratic control of Congress, a wave of positioning shifts hit the tape. Crude oil took the biggest immediate hit. WTI dropped more than 8 percent and slipped below the $90 mark. The logic was straightforward: markets assumed a reduced chance of further escalation in the Middle East, which pulled energy prices lower almost instantly.
That single move rippled outward. Oil and gas producers sold off, while anything tied to lower energy costs or consumer relief caught a bid. Home builders and related names finally caught a break. Home Depot pushed back into positive territory for the year, something it had not managed since August. Lower oil, softer Treasury yields, and hopes for some tariff relief all helped the housing complex. The 10-year yield dipped toward 4.9 percent, giving rate-sensitive sectors a little breathing room.
Consumer names also responded. The idea that cheaper energy would leave more money in household budgets lifted retailers and casual dining concepts. TJX Companies and Starbucks both found buyers. It felt like a classic risk-on rotation into areas that had been overlooked while the market obsessed over artificial intelligence infrastructure.
The Quiet Pain In Data Center And Power Names
Not everything rallied. Data center related stocks faced fresh pressure. There has been growing political pushback against rapid construction of large AI facilities, especially in states like Texas and Ohio. We had flagged this risk for several weeks heading into the midterms. The concern is less about the biggest hyperscalers and more about the fringe or speculative projects that may now face longer approval timelines or outright resistance.
Electrical equipment and power generation companies felt the impact. Names such as Eaton and GE Vernova came under selling pressure. Even strong earnings reports could not fully protect semiconductor names. AMD and Qnity Electronics both delivered better-than-expected results and constructive guidance, yet the stocks still struggled. The market was simply in a mood to question the speed of the AI buildout rather than celebrate near-term numbers.
Intel continued its rough stretch. Shares had already fallen hard since the end of September. On Wednesday the stock was lower again until a filing showed CEO Lip Bu Tan had bought 150,000 shares on Monday at an average price of roughly $64.73. That purchase helped the stock recover some of the day’s losses. It was encouraging to see the CEO put personal capital to work after a roughly 50 percent decline. At the same time, the move carries less weight than it normally would. Both the CEO and many outside investors had bought shares in the $90s earlier this year when the company raised about $20 billion. That earlier entry point remains a reminder that conviction alone does not always protect against further downside.
Hyperscalers Get A Different Reception
While pure-play AI infrastructure names stumbled, the companies actually funding the buildout behaved differently. Amazon, Alphabet, and Microsoft all advanced solidly. Meta Platforms finished slightly higher. The market appears to be making a distinction. If new rules or local opposition slow the pace of data center construction, the biggest cloud providers might actually benefit in the near term. Their aggressive capital expenditure programs have pushed several of them into negative free cash flow. Microsoft has stayed positive, yet free cash flow has declined more than 20 percent year over year in consecutive quarters.
A slower spending cycle could allow free cash flow to recover sooner than currently expected. It could also reduce the need for large debt or equity raises that dilute existing shareholders. In other words, a temporary pause in the most aggressive phase of the AI infrastructure race might be viewed as a positive for the balance sheets of the companies writing the biggest checks.
I find this distinction worth watching closely. The market is not abandoning the long-term AI story. It is simply becoming more selective about which parts of the ecosystem carry the least political and financing risk in the months ahead.
Why We Removed CVS Health From The Bullpen
Against that backdrop we made one portfolio decision. We are removing CVS Health from the Bullpen watchlist. We had added the name in early September alongside Kimberly-Clark while looking for defensive ideas that still offered reasonable valuations and respectable dividend yields. At the time the company appeared to be executing under CEO David Joyner, and the stock had pulled back on what looked like conservative 2027 earnings assumptions.
That story changed on Wednesday. The company announced plans to separate its national retail pharmacy business from the insurance operations under Aetna and the pharmacy benefit manager known as CVS Caremark. Creating two independent companies has clear strategic logic on paper. The retail pharmacy side faces intense competition and margin pressure, while the insurance and benefit manager businesses operate under different regulatory and growth dynamics.
The problem is timing. Management indicated the full separation is not expected to be completed until the first half of 2028. That is a long time for a stock to sit in what investors often call “spin purgatory.” During such extended periods, the shares can trade at a discount as the market waits for greater clarity on the capital structure, management teams, and standalone financial targets of the new entities.
We would rather wait until the separation process is further along and the market has a clearer line of sight on the two independent stories before considering the name again.
In my experience, these multi-year separations rarely deliver quick re-ratings. The process involves regulatory approvals, complex operational disentanglement, and the need to communicate two distinct investment cases to the market. Until those pieces fall into place, the stock often lacks a clear catalyst and can lag broader market moves.
Looking Ahead To The Next Batch Of Earnings
Wednesday’s closing bell brought results from McKesson, Qualcomm, Expedia, DoorDash, and Coherent. Thursday morning will feature reports from Kimberly-Clark and Cardinal Health, both of which remain on our radar. Other names scheduled to report include Cigna, Cummins, Parker Hannifin, Targa Resources, and Becton Dickinson.
On the economic calendar, the Labor Department will release weekly jobless claims, and we will also get the latest job-cut numbers from Challenger, Gray & Christmas. Those data points could influence the bond market and, by extension, the rate-sensitive sectors that performed well on Wednesday.
I remain cautious about reading too much into a single post-election session. The moves in AI infrastructure names and consumer stocks were sizable, yet policy details will take months to emerge. The same is true for any potential changes to the regulatory environment around data centers. A measured approach still feels appropriate.
Balancing Defensive Ideas With Growth Opportunities
Removing CVS does not mean we are abandoning the search for defensive exposure. Healthcare remains an important area for long-term portfolios, particularly when valuations look reasonable and balance sheets are solid. The challenge is finding names that do not carry multi-year corporate restructuring overhangs.
At the same time, the AI theme is not going away. Capital expenditure by the largest technology companies remains enormous. The question is simply the pace and the geographic concentration of new projects. Investors who can separate the long-term structural growth story from shorter-term political and financing noise may find opportunities in the coming quarters.
Oil prices, Treasury yields, and consumer spending power will continue to influence sector rotation. The sharp drop in crude on Wednesday served as a reminder of how quickly those relationships can shift when political uncertainty declines. Housing-related stocks and certain consumer discretionary names could continue to benefit if energy costs remain contained and rates edge lower.
Practical Considerations For Portfolio Construction
When a company announces a major separation that will take years to complete, the risk-reward profile changes. Liquidity can dry up in certain share classes. Analyst coverage sometimes fragments. Management attention naturally shifts toward the internal work required to split the businesses. All of those factors can keep a stock range-bound even if the broader market advances.
That is exactly the situation we now face with CVS Health. The original reasons for adding the name—attractive valuation, dividend support, and signs of operational improvement—remain partially valid. Yet the new timeline introduces a level of uncertainty that no longer fits the criteria we use for the Bullpen. We prefer ideas that can respond more quickly to improving fundamentals or shifting market sentiment.
- Monitor free cash flow trends at the largest technology spenders
- Watch local and federal developments around data center permitting
- Track energy prices as a leading indicator for consumer discretionary strength
- Reassess defensive healthcare names that lack multi-year restructuring risk
- Pay attention to any further insider purchases at beaten-down semiconductor companies
None of these items require immediate action. They simply form a framework for evaluating new information as it arrives. Markets rarely move in a straight line, and Wednesday’s session was a useful reminder of how quickly narratives can shift when political outcomes become clearer.
The Broader Context Of Recent Volatility
It is worth stepping back for a moment. Since late summer we have seen several sharp rotations. AI infrastructure names led for long stretches, then faced profit-taking. Defensive sectors attracted capital during periods of uncertainty, only to lag when risk appetite returned. The midterm results appear to have accelerated one of those rotations rather than created an entirely new trend.
Oil’s decline was the most dramatic single move, yet the drop in yields and the improvement in housing-related stocks also matter. Lower energy costs and slightly easier financial conditions tend to support broader economic activity over time. That backdrop could help companies that sell everyday goods and services more than it helps pure infrastructure builders in the near term.
I have found that the most durable portfolios usually contain a mix of growth exposure, quality defensive holdings, and enough flexibility to adjust when corporate strategies change. The decision on CVS Health is simply one example of that flexibility in action. Holding a name through a multi-year separation process is a legitimate strategy for some investors. It is not the approach we prefer for the watchlist at this moment.
What Comes Next For The AI Trade
The reaction in data center and power stocks should not be ignored, but it should also not be over-interpreted. Construction timelines for large facilities are measured in years, not months. Even if certain speculative projects face delays, the core demand from the largest cloud providers is unlikely to disappear. The more interesting question is whether those providers will moderate the pace of their own spending if external constraints tighten.
Microsoft, Amazon, Alphabet, and Meta have already committed enormous resources. A temporary slowdown could actually improve the optics of their free cash flow trajectories. Investors who have grown concerned about the capital intensity of the AI cycle may welcome any sign that spending growth is becoming more measured. That dynamic helped those stocks on Wednesday even as pure-play equipment providers faced pressure.
Semiconductor companies sit somewhere in the middle. They benefit from long-term AI demand yet remain sensitive to any perception that near-term capital expenditure plans are being scaled back. The mixed reaction to solid earnings from AMD and others illustrates that tension. Strong guidance is no longer enough if the market is questioning the sustainability of the broader spending cycle.
Keeping Perspective On Single-Day Moves
One of the hardest disciplines in markets is resisting the urge to rewrite every thesis after a single dramatic session. Wednesday delivered outsized moves in several directions. Oil collapsed. Certain consumer names surged. AI infrastructure stocks sold off. The largest technology companies advanced. Those shifts contain useful information, yet they do not rewrite the longer-term fundamental picture overnight.
Policy details around energy, trade, and infrastructure will emerge gradually. Corporate capital allocation decisions will evolve with those details. Earnings reports over the coming weeks will provide fresh data points on how companies themselves are interpreting the new environment. Until that information arrives, a balanced posture still makes the most sense.
We will continue to watch the names that report in the coming days, particularly those with exposure to both consumer spending and industrial activity. Kimberly-Clark and Cardinal Health should offer useful reads on defensive demand and healthcare trends. The industrial reports from Cummins and Parker Hannifin may shed light on the health of the broader manufacturing complex.
Final Thoughts On Portfolio Discipline
Removing a name from a watchlist is rarely dramatic. It is simply an acknowledgment that the original investment case has changed in a material way. For CVS Health, the multi-year timeline attached to the separation plan introduces a level of uncertainty that no longer fits our criteria. We will keep the broader healthcare sector under review and look for opportunities that offer clearer near-term catalysts.
At the same time, the post-election market action has highlighted both risks and opportunities across other parts of the market. Lower energy prices and softer yields support certain consumer and housing-related stocks. Political pressure on data center construction introduces a new variable into the AI infrastructure story. Insider buying at Intel provides a modest positive signal after a difficult period for the shares.
None of these developments require panic or euphoria. They simply require attention and a willingness to adjust when the facts change. That is the approach we intend to maintain in the sessions ahead. Markets will keep delivering new information. The job is to process that information without losing sight of the longer-term trends that ultimately drive returns.
The coming days of earnings and economic data should add further clarity. Until then, the decision on CVS Health stands as a straightforward application of process. When a story becomes more complicated and the timeline stretches further into the future, it is often better to step aside and wait for greater visibility. That is exactly what we have chosen to do.
